

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**MONTHLY FEE STATEMENT OF CORNERSTONE
RESEARCH FOR COMPENSATION FOR SERVICES
RENDERED AS CONSULTANT TO THE DEBTORS FOR
THE PERIOD FROM
NOVEMBER 1, 2020 THROUGH NOVEMBER 30, 2020**

Name of Applicant	Cornerstone Research
Applicant's Role in Case	Consultant to Purdue Pharma L.P., <i>et al.</i> ,
Date Order of Employment Signed	June 11, 2020
Period for which compensation and reimbursement is sought	November 1, 2020 through November 30, 2020

Summary of Total Fees and Expenses Requested	
Total compensation requested in this statement	\$698,217.60 (80% of \$872,772.00)
Total reimbursement requested in this statement	\$46.35
Total compensation and reimbursement requested in this statement	\$698,263.95

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

This is a(n): ☒ Monthly Application ☐ Interim Application ☐ Final Application

Pursuant to sections 327, 330, and 331 of chapter 11 of title 11 of the United States Code (the “**Bankruptcy Code**”), Rule 2016 of the Federal Rules of Bankruptcy Procedure (the “**Bankruptcy Rules**”), Rule 2016-1 of the Local Bankruptcy Rules for the United States Bankruptcy Court for the Southern District of New York (the “**Local Rules**”), the *Order Authorizing the Retention and Employment of Cornerstone Research as Consultants for the Debtors Nunc Pro Tunc to January 14, 2020* [ECF No. 1255] (the “**Retention Order**”), and the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals*, dated November 21, 2019 [Docket No. 529] (the “**Interim Compensation Order**”), Cornerstone Research, consultant for the above-captioned debtors and debtors in possession (collectively, the “**Debtors**”), submits this *Monthly Fee Statement of Cornerstone Research for Services Rendered as Consultant to the Debtor for the Period from November 1, 2020 Through November 30, 2020* (this “**Fee Statement**”).² By this Fee Statement, Cornerstone Research seeks (i) compensation in the amount of **\$698,217.60**, which is equal to 80% of the total amount of reasonable compensation for actual, necessary consulting services that Cornerstone Research incurred in connection with such services during the Fee Period (i.e., **\$872,772.00**) and ii) payment of **\$46.35** for the actual, necessary expenses that Cornerstone Research incurred in connection with such services during the Fee Period.

² The period from November 1, 2020 through and including November 30, 2020, is referred to herein as the “**Fee Period**.”

Itemization of Services Rendered and Disbursements Incurred

1. Attached hereto as **Exhibit A** is a chart of the number of hours expended and fees incurred (on an aggregate basis) by Cornerstone Research consultants and litigation support staff during the Fee Period with respect to each project category. As reflected in **Exhibit A**, Cornerstone Research incurred **\$872,772.00** in fees during the Fee Period. Pursuant to this Fee Statement, Cornerstone Research seeks reimbursement for 80% of such fees, totaling **\$698,217.60**.

2. Attached hereto as **Exhibit B** is a chart of Cornerstone Research staff, including the standard hourly rate for each consultant and litigation support staff member who rendered services to the Debtors in connection with these chapter 11 cases during the Fee Period and the title, hourly rate, aggregate hours worked and the amount of fees earned by each individual. The blended hourly billing rate of consultants for all services provided during the Fee Period is \$450.30.³

3. Attached hereto as **Exhibit C** is a chart of expenses that Cornerstone Research incurred or disbursed in the amount of **\$46.35** in connection with providing professional services to the Debtors during the Fee Period.

4. Attached hereto as **Exhibit D** are the time records of Cornerstone Research for The Fee Period organized by month and project category with a daily time log describing the time spent by each consultant and litigation support staff member during Fee Period.

Notice

5. The Debtors will provide notice of this Fee Statement in accordance with the Interim Compensation Order. The Debtors submit that no other or further notice be given.

[Remainder of Page Left Blank Intentionally]

³ The blended hourly billing rate of \$450.30 for consultants is derived by dividing the total fees for consultants of \$872,772.00 by the total hours of 1938.20.

WHEREFORE, Cornerstone Research, in connection with services rendered on behalf of the Debtors, respectfully requests (i) compensation in the amount of **\$698,217.60** which is equal to 80% of the total amount of reasonable compensation for actual, necessary consulting services that Cornerstone Research incurred in connection with such services during the Fee Period (i.e., **\$872,772.00**) and ii) payment of **\$46.35** for the actual, necessary expenses that Cornerstone Research incurred in connection with such services during the Fee Period.

Dated: December 30, 2020
Boston, Massachusetts

CORNERSTONE RESEARCH

By: /s/ Sally Woodhouse

699 Boylston Street
Boston, Massachusetts 02116
Telephone: (617) 927-3000
Facsimile: (617) 927-3100

Exhibit A

Fees By Project Category

Project Category	Total Hours	Total Fees
Preparation of Fee Statements	14.40	\$ 9,964.00
Claims Valuation	1923.80	\$ 862,808.00
Total	1938.20	\$ 872,772.00

Exhibit B

Professional and Paraprofessional Fees

Individual	Title	Hourly Rate	Total Hours Billed	Total Compensation
Professional Fees				
Kovacheva, Penka	Principal	\$ 720.00	64.70	\$ 46,584.00
Haque, Rezwan	Senior Manager	\$ 645.00	110.00	\$ 70,950.00
Lee, James	Senior Manager	\$ 645.00	87.30	\$ 56,308.50
Abraham, Sarah M.	Manager	\$ 605.00	117.00	\$ 70,785.00
Guo, Fang	Manager	\$ 605.00	103.90	\$ 62,859.50
Yanguas, Maria Lucia	Associate	\$ 545.00	164.80	\$ 89,816.00
Popov, Anton	Associate	\$ 495.00	72.90	\$ 36,085.50
Russell, Nolan P.	Research Associate	\$ 450.00	46.00	\$ 20,700.00
King, Kyla M.	Research Associate	\$ 410.00	170.90	\$ 70,069.00
Desmedt, Maaike	Senior Analyst	\$ 380.00	49.60	\$ 18,848.00
McGill, Jeffrey S.	Senior Analyst	\$ 380.00	159.90	\$ 60,762.00
Aristidou, Andreas	Summer Associate	\$ 360.00	168.70	\$ 60,732.00
Chen, Yixin	Analyst	\$ 345.00	96.40	\$ 33,258.00
Guo, Ruihan	Analyst	\$ 345.00	92.60	\$ 31,947.00
Miller, Robert M.	Analyst	\$ 345.00	85.70	\$ 29,566.50
Delsman, Benjamin P.	Analyst	\$ 345.00	88.20	\$ 30,429.00
Bazak, Eric R.	Analyst	\$ 320.00	115.00	\$ 36,800.00
Lan, Yuehan	Analyst	\$ 320.00	59.80	\$ 19,136.00
Nandwani, Gehna	Analyst	\$ 320.00	84.80	\$ 27,136.00
		Total	1938.20	\$ 872,772.00

Exhibit C

Expense Summary

Expense Category	Service Provider (if applicable)	Total Expenses
Document/Data Acquisition	Journal Article	\$ 46.35
Total		\$ 46.35

Exhibit D

Time Detail by Project Category and Month

Project Category: Preparation of Fee Statements

Timekeeper	Date	Hours	Narrative
Guo, Fang	11/4/2020	1.0	Reviewed time details for monthly fee statement.
Kovacheva, Penka	11/4/2020	0.2	Reviewed time details for monthly fee statement.
Guo, Fang	11/5/2020	1.4	Reviewed time details for monthly fee statement.
Kovacheva, Penka	11/5/2020	0.3	Reviewed time details for monthly fee statements.
Haque, Rezwan	11/6/2020	0.5	Reviewed time details for monthly fee statement.
Kovacheva, Penka	11/6/2020	0.8	Reviewed interim fee application.
Lee, James	11/6/2020	0.7	Reviewed time details for monthly fee statement.
Abraham, Sarah M.	11/8/2020	0.2	Reviewed time details for monthly fee statement.
Kovacheva, Penka	11/8/2020	2.4	Checked and updated interim fee application.
Haque, Rezwan	11/9/2020	0.2	Reviewed time details for monthly fee statement.
Kovacheva, Penka	11/9/2020	2.0	Checked and updated interim fee application.
Kovacheva, Penka	11/10/2020	0.6	Updated interim fee application.
Kovacheva, Penka	11/11/2020	0.3	Reviewed time details for monthly fee statement.
Kovacheva, Penka	11/13/2020	0.7	Updated interim fee application.
Kovacheva, Penka	11/15/2020	0.8	Reviewed and updated time details for monthly fee statement.
Kovacheva, Penka	11/16/2020	0.3	Finalized interim fee application.
Kovacheva, Penka	11/24/2020	1.0	Updated monthly fee statement.
Kovacheva, Penka	11/25/2020	0.2	Reviewed and updated monthly fee statement.
Kovacheva, Penka	11/30/2020	0.8	Updated and finalized monthly fee statement.

Total **14.4**

Project Category: Claims Valuation

Timekeeper	Date	Hours	Narrative
Abraham, Sarah M.	11/2/2020	1.0	Investigated data sources for third-party payer claims valuation.
Aristidou, Andreas	11/2/2020	1.6	Reviewed public claimants' backup materials.
Aristidou, Andreas	11/2/2020	6.5	Reviewed expert reports for third-party payer claim valuation estimation.
Bazak, Eric R.	11/2/2020	0.3	Performed sensitivity analysis on public claims.
Bazak, Eric R.	11/2/2020	1.0	Researched drug use survey data.
Bazak, Eric R.	11/2/2020	2.4	Calculated future projection sensitivities for public claims estimates.
Chen, Yixin	11/2/2020	1.4	Conducted sensitivity analysis on population projection.
Guo, Fang	11/2/2020	0.9	Corresponded with state claimants' economic consultants regarding data requests.
Guo, Fang	11/2/2020	3.4	Reviewed public claim valuation sensitivity analysis.
Guo, Ruihan	11/2/2020	2.9	Analyzed pharmaceutical market data.
Haque, Rezwan	11/2/2020	0.8	Reviewed academic literature on pharmaceutical marketing.
Haque, Rezwan	11/2/2020	1.2	Reviewed data on hospital costs.
Haque, Rezwan	11/2/2020	1.8	Reviewed academic literature on hospital costs.
King, Kyla M.	11/2/2020	1.7	Reviewed public claimants' backup materials.
King, Kyla M.	11/2/2020	2.1	Checked sensitivity analyses of state claimants' estimates.
King, Kyla M.	11/2/2020	3.7	Analyzed pharmaceutical market data.
Kovacheva, Penka	11/2/2020	1.1	Reviewed and directed analysis of pharmaceutical market data.
Lan, Yuehan	11/2/2020	2.4	Reviewed prescription data for third-party payer claims valuations.
Lee, James	11/2/2020	2.2	Outlined next steps for third-party payer claims analyses.
McGill, Jeffrey S.	11/2/2020	3.9	Prepared for analyses data for third-party payer valuation.
Miller, Robert M.	11/2/2020	0.7	Analyzed public claims future cost sensitivities.
Abraham, Sarah M.	11/3/2020	1.5	Investigated data availability for third-party payer claims valuation.

Aristidou, Andreas	11/3/2020	4.0	Analyzed state claimants' future projection model.
Aristidou, Andreas	11/3/2020	5.1	Reviewed academic literature on pharmaceutical marketing.
Bazak, Eric R.	11/3/2020	0.5	Checked sensitivity analysis of future projections.
Bazak, Eric R.	11/3/2020	0.8	Researched drug use survey data.
Bazak, Eric R.	11/3/2020	4.0	Checked state claims exhibit.
Chen, Yixin	11/3/2020	1.8	Conducted sensitivity analysis on future population projection.
Chen, Yixin	11/3/2020	3.8	Collected hospital cost data for claims valuation analysis.
Delsman, Benjamin P.	11/3/2020	1.3	Prepared for analysis hospital cost data.
Guo, Fang	11/3/2020	0.3	Reviewed public claims backup materials produced by states' consultants.
Guo, Fang	11/3/2020	0.4	Provided comments on hospital claims valuation analysis.
Guo, Fang	11/3/2020	3.2	Prepared work plan for robustness checks of future projections.
Guo, Fang	11/3/2020	3.6	Reviewed public claims sensitivity analyses.
Guo, Ruihan	11/3/2020	4.8	Reviewed prescription pricing data.
Haque, Rezwan	11/3/2020	0.8	Reviewed academic literature on hospital costs.
Haque, Rezwan	11/3/2020	1.3	Reviewed academic literature on pharmaceutical marketing.
Haque, Rezwan	11/3/2020	1.3	Reviewed work plan for analysis of hospital claims.
King, Kyla M.	11/3/2020	2.1	Performed robustness checks of state claimants' estimates.
King, Kyla M.	11/3/2020	2.3	Checked pharmaceutical market data.
King, Kyla M.	11/3/2020	2.5	Checked sensitivity analyses of state claimants' estimates.
Kovacheva, Penka	11/3/2020	0.2	Reviewed methodology for analyzing pharmaceutical market data.
Lan, Yuehan	11/3/2020	5.6	Reviewed prescription and cost data for third-party payer claims valuations.
Lee, James	11/3/2020	1.6	Reviewed analyses related to third-party-payer claims.
McGill, Jeffrey S.	11/3/2020	2.8	Analyzed data for third-party payer valuation.
Miller, Robert M.	11/3/2020	1.0	Updated public claims exhibit.
Miller, Robert M.	11/3/2020	2.1	Analyzed opioid use projections.
Popov, Anton	11/3/2020	0.7	Reviewed mortality data and hospital cost data sources.

Popov, Anton	11/3/2020	0.9	Reviewed academic literature and methodology of hospital cost estimation.
Yanguas, Maria Lucia	11/3/2020	0.6	Reviewed work plan for population projection sensitivities.
Yanguas, Maria Lucia	11/3/2020	2.4	Reviewed healthcare cost data for hospital claims valuation analyses.
Abraham, Sarah M.	11/4/2020	1.9	Managed valuation analyses of third-party payer claims.
Aristidou, Andreas	11/4/2020	2.6	Reviewed public claimants' backup materials.
Aristidou, Andreas	11/4/2020	6.7	Reviewed and summarized academic literature on pharmaceutical marketing.
Bazak, Eric R.	11/4/2020	0.5	Checked state claims exhibit.
Chen, Yixin	11/4/2020	0.8	Checked exhibits for future population projection.
Chen, Yixin	11/4/2020	2.1	Checked sensitivity analysis on future population projection.
Chen, Yixin	11/4/2020	3.7	Conducted sensitivity analysis on future population projection.
Chen, Yixin	11/4/2020	3.9	Summarized hospital cost data for analysis.
Delsman, Benjamin P.	11/4/2020	1.3	Reviewed analysis of hospital claims.
Delsman, Benjamin P.	11/4/2020	2.5	Reviewed documentation for hospital data.
Delsman, Benjamin P.	11/4/2020	2.8	Prepared for analysis hospital cost data.
Guo, Fang	11/4/2020	3.6	Reviewed public claims sensitivity analyses.
Guo, Ruihan	11/4/2020	2.3	Reviewed documentation for prescription pricing data.
Guo, Ruihan	11/4/2020	2.6	Analyzed prescription pricing data.
Guo, Ruihan	11/4/2020	4.9	Collected and analyzed prescription pricing data.
Haque, Rezwan	11/4/2020	0.7	Reviewed estimation of prescription opioid market shares.
Haque, Rezwan	11/4/2020	0.8	Reviewed data on hospital costs.
Haque, Rezwan	11/4/2020	1.5	Coordinated analyses of hospital claims valuation.
Haque, Rezwan	11/4/2020	2.2	Reviewed academic literature on hospital costs.
King, Kyla M.	11/4/2020	1.5	Performed robustness checks of state claimants' estimates.
King, Kyla M.	11/4/2020	2.4	Updated state claim analysis exhibits.
King, Kyla M.	11/4/2020	3.3	Checked sensitivity analyses of state claimants' estimates.
Kovacheva, Penka	11/4/2020	1.3	Reviewed and directed methodology for commercial claims estimation.

Lan, Yuehan	11/4/2020	3.4	Summarized pharmaceutical market data for claims valuations.
Lee, James	11/4/2020	0.7	Reviewed analyses of third-party payer claims.
McGill, Jeffrey S.	11/4/2020	3.8	Prepared draft tables of third-party payer claims valuations.
Miller, Robert M.	11/4/2020	0.7	Updated public claims exhibit.
Miller, Robert M.	11/4/2020	0.9	Researched hospital cost data.
Miller, Robert M.	11/4/2020	3.1	Analyzed drug use survey data.
Popov, Anton	11/4/2020	0.9	Reviewed data for hospital cost estimation.
Popov, Anton	11/4/2020	1.4	Reviewed academic literature on hospital costs.
Popov, Anton	11/4/2020	4.0	Summarized academic literature on hospital costs.
Russell, Nolan P.	11/4/2020	1.3	Updated future projection analysis.
Russell, Nolan P.	11/4/2020	2.3	Created exhibits for future projection sensitivities.
Russell, Nolan P.	11/4/2020	3.8	Conducted sensitivity analyses on future projections.
Yanguas, Maria Lucia	11/4/2020	3.3	Reviewed work plan for hospital claims valuation and sensitivities.
Yanguas, Maria Lucia	11/4/2020	3.8	Reviewed and summarized literature on hospital costs.
Abraham, Sarah M.	11/5/2020	1.0	Call with expert to discuss third-party payer claims valuation.
Abraham, Sarah M.	11/5/2020	1.3	Prepared work plan for valuation of third-party payer claims with team.
Aristidou, Andreas	11/5/2020	2.9	Reviewed and summarized academic literature on pharmaceutical marketing.
Aristidou, Andreas	11/5/2020	6.7	Performed sensitivity analyses of public claims.
Bazak, Eric R.	11/5/2020	2.3	Checked state claims exhibit.
Bazak, Eric R.	11/5/2020	2.8	Updated state claims exhibit.
Chen, Yixin	11/5/2020	2.1	Summarized hospital cost data for claims valuation analysis.
Chen, Yixin	11/5/2020	3.2	Reviewed documentation of hospital cost data.
Delsman, Benjamin P.	11/5/2020	1.7	Checked hospital cost data.
Delsman, Benjamin P.	11/5/2020	2.1	Reviewed documentation for hospital cost data.
Guo, Fang	11/5/2020	1.0	Discussed with expert public claims valuation analyses.
Guo, Fang	11/5/2020	1.3	Reviewed summary of public claims sensitivity analyses for expert call.

Guo, Fang	11/5/2020	2.7	Prepared work plan for public claims sensitivity analyses.
Guo, Ruihan	11/5/2020	1.1	Reviewed and analyzed opioid prescriptions data.
Guo, Ruihan	11/5/2020	2.1	Analyzed opioid prescription pricing data.
Haque, Rezwan	11/5/2020	0.8	Prepared agenda for call with counsel regarding hospital claims analyses.
Haque, Rezwan	11/5/2020	0.8	Reviewed work plan for analysis of hospital claims.
Haque, Rezwan	11/5/2020	0.8	Reviewed data on hospital costs.
Haque, Rezwan	11/5/2020	1.0	Call with expert to discuss hospital claims valuation analyses.
King, Kyla M.	11/5/2020	3.4	Checked sensitivity analyses of state claimants' estimates.
King, Kyla M.	11/5/2020	3.8	Performed robustness checks of state claimants' estimates.
Kovacheva, Penka	11/5/2020	0.6	Reviewed methodology for public entities' claims estimation.
Kovacheva, Penka	11/5/2020	0.7	Reviewed materials from hospital claimants regarding claims estimation.
Kovacheva, Penka	11/5/2020	1.0	Call with expert regarding public and commercial entities' claims estimation.
Lan, Yuehan	11/5/2020	2.2	Reviewed pharmaceutical market data on opioid prescriptions.
Lee, James	11/5/2020	0.3	Prepared materials for call with counsel regarding third-party payer analyses.
Lee, James	11/5/2020	0.5	Prepared materials regarding third-party payer claims for call with expert.
Lee, James	11/5/2020	1.0	Call with expert regarding third-party payer claims analyses.
Lee, James	11/5/2020	1.0	Reviewed analyses of prescription data for third-party payer claims valuations.
McGill, Jeffrey S.	11/5/2020	1.7	Investigated prescription and cost data used in third-party payer valuations.
McGill, Jeffrey S.	11/5/2020	1.8	Checked datasets for third-party payer valuations.
McGill, Jeffrey S.	11/5/2020	3.8	Conducted sensitivities analyses of third-party payer claims valuation.
Miller, Robert M.	11/5/2020	1.2	Checked public claims exhibit.
Miller, Robert M.	11/5/2020	3.7	Updated state claims exhibit.
Popov, Anton	11/5/2020	1.6	Analyzed academic studies' methodology for hospital costs estimation.
Popov, Anton	11/5/2020	2.4	Analyzed data and methodology for statistical estimation of hospital costs.
Russell, Nolan P.	11/5/2020	1.3	Analyzed opioid use projections.

Russell, Nolan P.	11/5/2020	2.5	Prepared exhibit for hospital claims analysis.
Yanguas, Maria Lucia	11/5/2020	4.0	Reviewed hospital claims valuation analyses.
Yanguas, Maria Lucia	11/5/2020	4.4	Reviewed data and documentation for hospital claims valuation.
Abraham, Sarah M.	11/6/2020	1.3	Call with counsel regarding third-party payer claims valuation.
Abraham, Sarah M.	11/6/2020	1.7	Managed estimation of third-party payer claims valuation.
Aristidou, Andreas	11/6/2020	0.3	Discussed public claims valuation with team.
Aristidou, Andreas	11/6/2020	9.6	Summarized academic literature on pharmaceutical marketing.
Chen, Yixin	11/6/2020	1.1	Reviewed documentation of hospital cost data.
Delsman, Benjamin P.	11/6/2020	1.1	Performed preliminary data analysis of hospital cost data.
Delsman, Benjamin P.	11/6/2020	2.8	Checked hospital cost data.
Delsman, Benjamin P.	11/6/2020	3.2	Reviewed documentation for hospital cost data.
Guo, Fang	11/6/2020	0.5	Discussed public claims valuation analysis with team.
Guo, Fang	11/6/2020	0.6	Organized sensitivity analyses of NAS claims.
Guo, Fang	11/6/2020	1.2	Discussed with counsel public claims valuation analysis.
Guo, Fang	11/6/2020	1.4	Reviewed sensitivity analyses of public claims.
Guo, Fang	11/6/2020	1.8	Prepared for client call regarding public claims and NAS claims valuation.
Haque, Rezwan	11/6/2020	0.4	Discussed hospital claims valuation analyses with team.
Haque, Rezwan	11/6/2020	1.2	Call with counsel to discuss hospital claims valuation analyses.
Haque, Rezwan	11/6/2020	1.7	Reviewed data on hospital costs.
Haque, Rezwan	11/6/2020	1.8	Reviewed academic literature on hospital costs.
King, Kyla M.	11/6/2020	0.5	Reviewed public claimants' backup materials.
King, Kyla M.	11/6/2020	1.1	Checked sensitivity analyses of state claimants' estimates.
King, Kyla M.	11/6/2020	3.2	Performed robustness checks of state claimants' estimates.
Kovacheva, Penka	11/6/2020	0.4	Discussed private and public claims estimation with team members.

Kovacheva, Penka	11/6/2020	1.1	Reviewed and directed analysis of hospitals' claims estimation.
Kovacheva, Penka	11/6/2020	1.1	Call with counsel regarding claims estimation of private and government claimants.
Lan, Yuehan	11/6/2020	1.4	Reviewed pharmaceutical market data for claims valuations.
Lee, James	11/6/2020	0.4	Discussed third-party payer claims valuation analyses with team.
Lee, James	11/6/2020	1.0	Analyzed personal injury claims data.
Lee, James	11/6/2020	1.0	Reviewed academic literature on pharmaceutical marketing.
Lee, James	11/6/2020	1.3	Call with counsel regarding third-party payer claims valuation analyses.
McGill, Jeffrey S.	11/6/2020	1.9	Checked datasets for third-party payer claims valuations.
McGill, Jeffrey S.	11/6/2020	3.6	Updated methodology for third-party payer claims valuations.
Miller, Robert M.	11/6/2020	1.7	Updated public claims exhibit.
Popov, Anton	11/6/2020	1.1	Analyzed data on hospital costs.
Popov, Anton	11/6/2020	1.6	Reviewed academic literature on hospital costs.
Yanguas, Maria Lucia	11/6/2020	0.4	Discussed hospital claims valuation analyses with team.
Yanguas, Maria Lucia	11/6/2020	0.5	Analyzed personal injury claims data.
Yanguas, Maria Lucia	11/6/2020	2.2	Reviewed academic literature for hospital claims valuation.
Yanguas, Maria Lucia	11/6/2020	4.0	Reviewed documentation for hospital cost data.
Kovacheva, Penka	11/7/2020	0.5	Directed analyses of commercial claims estimation.
Popov, Anton	11/7/2020	1.3	Summarized academic literature on economic burden of opioid epidemic.
Yanguas, Maria Lucia	11/7/2020	0.8	Reviewed academic literature on hospital costs.
Abraham, Sarah M.	11/8/2020	0.4	Revised estimation methodology for third-party payer claims valuation.
Aristidou, Andreas	11/8/2020	2.3	Reviewed academic literature on pharmaceutical marketing.
Chen, Yixin	11/8/2020	2.7	Analyzed summary statistics for hospital cost data.
Delsman, Benjamin P.	11/8/2020	2.4	Conducted sensitivity checks on hospital cost data.
Abraham, Sarah M.	11/9/2020	3.3	Managed valuation of third-party payer claims.
Aristidou, Andreas	11/9/2020	2.5	Reviewed estimates of third-party payer claims.

Aristidou, Andreas	11/9/2020	3.8	Updated summary of academic literature on pharmaceutical marketing.
Aristidou, Andreas	11/9/2020	3.9	Reviewed academic literature on pharmaceutical marketing.
Bazak, Eric R.	11/9/2020	0.5	Checked drug use survey data.
Bazak, Eric R.	11/9/2020	1.3	Created exhibit on NAS claims.
Chen, Yixin	11/9/2020	1.1	Summarized methodology and assumptions for analysis of hospital cost data.
Chen, Yixin	11/9/2020	3.7	Prepared for analysis hospital cost data and opioid use population data.
Delsman, Benjamin P.	11/9/2020	1.3	Analyzed data on opioid use population and demographic characteristics.
Delsman, Benjamin P.	11/9/2020	2.1	Checked hospital cost data.
Delsman, Benjamin P.	11/9/2020	3.9	Created dataset for hospital claims analyses.
Guo, Fang	11/9/2020	3.3	Reviewed sensitivity analyses of public claims.
Guo, Ruihan	11/9/2020	1.8	Conducted research on opioid products available in prescription pricing data.
Guo, Ruihan	11/9/2020	4.9	Analyzed opioid prescription pricing data.
Haque, Rezwan	11/9/2020	2.1	Reviewed analysis of hospital claims.
Haque, Rezwan	11/9/2020	2.3	Reviewed academic literature on hospital costs.
King, Kyla M.	11/9/2020	2.3	Reviewed public claimants' backup.
King, Kyla M.	11/9/2020	2.5	Checked sensitivity analyses of state claimants' estimates.
King, Kyla M.	11/9/2020	3.9	Performed robustness checks of state claimants' estimates.
Kovacheva, Penka	11/9/2020	0.6	Reviewed methodology for estimating personal injury and commercial claims.
Lan, Yuehan	11/9/2020	0.9	Assessed data sources for use in third-party payer claims valuations.
Lee, James	11/9/2020	1.5	Analyzed prescriptions data for third-party payer claims valuation analyses.
McGill, Jeffrey S.	11/9/2020	1.9	Conducted sensitivity analyses of third-party payer claims valuation.
McGill, Jeffrey S.	11/9/2020	3.7	Calculated statistics for public claims analyses.
McGill, Jeffrey S.	11/9/2020	3.8	Analyzed data for third-party payer analyses and prepared draft tables.
Miller, Robert M.	11/9/2020	1.6	Checked public claims exhibit.
Popov, Anton	11/9/2020	1.7	Reviewed academic literature on hospital costs.
Popov, Anton	11/9/2020	2.7	Analyzed data for estimation of hospital costs.

Russell, Nolan P.	11/9/2020	1.0	Checked hospital claims estimates.
Russell, Nolan P.	11/9/2020	2.8	Updated exhibit on estimates of hospital claims.
Yanguas, Maria Lucia	11/9/2020	0.8	Reviewed sensitivities for hospital claims valuation.
Yanguas, Maria Lucia	11/9/2020	2.3	Reviewed academic literature for hospital costs.
Yanguas, Maria Lucia	11/9/2020	2.5	Reviewed methodology for calculating hospital claims.
Yanguas, Maria Lucia	11/9/2020	3.8	Reviewed academic literature for hospital claims valuation.
Abraham, Sarah M.	11/10/2020	4.9	Managed valuation of third-party payer claims.
Aristidou, Andreas	11/10/2020	2.1	Checked calculations for third-party payer claim valuations.
Aristidou, Andreas	11/10/2020	3.9	Reviewed academic literature on pharmaceutical marketing.
Aristidou, Andreas	11/10/2020	3.9	Summarized methodology for estimation of third-party payer claims.
Bazak, Eric R.	11/10/2020	0.6	Updated state claims sensitivity analyses.
Bazak, Eric R.	11/10/2020	1.0	Calculated historical state healthcare costs.
Bazak, Eric R.	11/10/2020	1.0	Created NAS claims exhibit.
Chen, Yixin	11/10/2020	3.9	Updated dataset for hospital claims analyses.
Delsman, Benjamin P.	11/10/2020	0.7	Summarized methodology regarding analysis of hospital cost data.
Delsman, Benjamin P.	11/10/2020	1.5	Checked hospital cost data.
Guo, Fang	11/10/2020	0.4	Call with state claimants' consultants regarding public claims valuation analyses.
Guo, Fang	11/10/2020	3.8	Prepared work plan to estimate public claimants' historical costs.
Guo, Ruihan	11/10/2020	3.9	Analyzed opioid prescription pricing data.
Haque, Rezwan	11/10/2020	2.3	Reviewed analysis of hospital claims.
Haque, Rezwan	11/10/2020	2.4	Reviewed data on hospital costs.
Haque, Rezwan	11/10/2020	2.8	Reviewed academic literature on hospital costs.
King, Kyla M.	11/10/2020	1.2	Checked sensitivities of NAS claimant costs.
King, Kyla M.	11/10/2020	1.5	Performed robustness checks of state claimants' estimates.
King, Kyla M.	11/10/2020	3.0	Checked sensitivity analyses of state claimants' estimates.
King, Kyla M.	11/10/2020	3.1	Analyzed pharmaceutical market data.

Kovacheva, Penka	11/10/2020	0.4	Call with state claimants' consultants regarding public claims estimation.
Kovacheva, Penka	11/10/2020	1.4	Reviewed methodology for hospital claims estimation.
Kovacheva, Penka	11/10/2020	1.7	Reviewed and managed sensitivity analyses of public claims estimates.
Lan, Yuehan	11/10/2020	1.7	Analyzed prescription data for third-party payer claims valuations.
Lee, James	11/10/2020	0.7	Reviewed summary of academic papers regarding pharmaceutical marketing.
Lee, James	11/10/2020	0.8	Reviewed analysis of pharmaceutical market data.
McGill, Jeffrey S.	11/10/2020	2.6	Researched cost data used in third-party payer claims valuations.
McGill, Jeffrey S.	11/10/2020	2.8	Checked statistics used in public claims analysis.
McGill, Jeffrey S.	11/10/2020	3.9	Analyzed prescription data used in third-party payer claims valuations.
Miller, Robert M.	11/10/2020	2.0	Checked future projection sensitivities.
Miller, Robert M.	11/10/2020	2.8	Updated public claims exhibits.
Popov, Anton	11/10/2020	1.2	Reviewed academic literature on hospital costs.
Popov, Anton	11/10/2020	3.0	Calculated estimates of hospital costs.
Yanguas, Maria Lucia	11/10/2020	3.2	Reviewed methodology and literature estimates for hospital claims valuation.
Yanguas, Maria Lucia	11/10/2020	3.8	Updated analyses of personal injury claims valuation.
Abraham, Sarah M.	11/11/2020	5.9	Managed third-party payer claims valuation.
Aristidou, Andreas	11/11/2020	2.1	Reviewed public claimants' backup materials.
Aristidou, Andreas	11/11/2020	2.7	Summarized academic literature on pharmaceutical marketing.
Aristidou, Andreas	11/11/2020	3.8	Updated summary of third-party payer claims calculations.
Bazak, Eric R.	11/11/2020	0.4	Updated state claims analysis.
Bazak, Eric R.	11/11/2020	0.6	Prepared NAS claims exhibit.
Bazak, Eric R.	11/11/2020	3.1	Calculated historical state healthcare costs.
Bazak, Eric R.	11/11/2020	4.5	Prepared data for calculating historical state healthcare costs.
Chen, Yixin	11/11/2020	1.9	Prepared exhibit summarizing hospital claims analyses.
Chen, Yixin	11/11/2020	3.1	Analyzed hospital cost data.
Delsman, Benjamin P.	11/11/2020	4.3	Analyzed relationship between opioid use population and hospital costs.

Guo, Fang	11/11/2020	1.1	Reviewed and edited exhibit on NAS claims valuation.
Guo, Fang	11/11/2020	1.9	Designed sensitivity analyses of public claims valuation.
Guo, Ruihan	11/11/2020	1.9	Checked analyses of opioid prescription pricing data.
Guo, Ruihan	11/11/2020	3.8	Analyzed opioid prescription pricing data and summarized findings.
Haque, Rezwan	11/11/2020	0.3	Corresponded with counsel regarding hospital claims.
Haque, Rezwan	11/11/2020	3.3	Prepared summary of academic literature on hospital costs.
King, Kyla M.	11/11/2020	0.5	Checked sensitivities of NAS claimant costs.
King, Kyla M.	11/11/2020	1.7	Analyzed pharmaceutical market data.
King, Kyla M.	11/11/2020	2.4	Checked sensitivity analyses of state claimants' estimates.
King, Kyla M.	11/11/2020	3.6	Performed robustness checks of state claimants' estimates.
Kovacheva, Penka	11/11/2020	0.5	Reviewed sensitivity analyses of personal injury claims estimation.
Lan, Yuehan	11/11/2020	3.4	Analyzed prescription data for third-party payer claims valuations.
Lan, Yuehan	11/11/2020	4.0	Calculated summary statistics for prescription data.
Lee, James	11/11/2020	0.8	Prepared materials related to personal injury claims analysis for call with expert.
Lee, James	11/11/2020	1.4	Reviewed academic papers on pharmaceutical marketing.
Lee, James	11/11/2020	2.2	Analyzed personal injury claims data.
McGill, Jeffrey S.	11/11/2020	1.6	Prepared memorandum summarizing methodology for third-party payer claims analyses.
McGill, Jeffrey S.	11/11/2020	2.4	Analyzed opioid prescription data used in third-party payer claims valuations.
McGill, Jeffrey S.	11/11/2020	3.7	Updated data used in third-party payer claims valuation.
Miller, Robert M.	11/11/2020	0.5	Updated public claims exhibit.
Miller, Robert M.	11/11/2020	2.7	Checked medical cost calculations for public claims analyses.
Popov, Anton	11/11/2020	1.6	Designed methodology for estimating hospital costs.
Popov, Anton	11/11/2020	1.7	Reviewed data for estimation of hospital costs.
Yanguas, Maria Lucia	11/11/2020	1.7	Designed methodology for analysis of hospital claims valuation.

Yanguas, Maria Lucia	11/11/2020	3.9	Reviewed articles on hospital costs to be sent to expert.
Yanguas, Maria Lucia	11/11/2020	5.4	Reviewed and updated analysis of personal injury claims valuation.
Abraham, Sarah M.	11/12/2020	1.0	Call with expert regarding personal injury claims valuation.
Abraham, Sarah M.	11/12/2020	1.1	Call with expert regarding third-party payer claims valuation.
Abraham, Sarah M.	11/12/2020	3.9	Managed third-party payer claims valuation.
Aristidou, Andreas	11/12/2020	2.2	Reviewed public claimants' backup materials.
Aristidou, Andreas	11/12/2020	3.6	Reviewed academic literature on pharmaceutical marketing.
Bazak, Eric R.	11/12/2020	2.2	Prepared exhibit for NAS claims.
Bazak, Eric R.	11/12/2020	2.6	Checked historical state healthcare cost calculations.
Chen, Yixin	11/12/2020	3.5	Checked analysis of hospital cost data.
Chen, Yixin	11/12/2020	4.0	Conducted sensitivity analyses of hospital cost data.
Delsman, Benjamin P.	11/12/2020	2.1	Analyzed relations between opioid use population and hospital costs.
Delsman, Benjamin P.	11/12/2020	3.2	Performed sensitivity analyses of hospital claims estimation.
Guo, Fang	11/12/2020	1.0	Discussed with expert public claims valuation.
Guo, Fang	11/12/2020	1.1	Reviewed and edited NAS claims exhibit.
Guo, Fang	11/12/2020	2.2	Reviewed backup materials produced by states' consultants.
Guo, Fang	11/12/2020	2.3	Reviewed estimates of public claimants' historical costs.
Guo, Fang	11/12/2020	2.7	Reviewed sensitivity analysis of public claims valuation.
Guo, Ruihan	11/12/2020	1.3	Updated analyses of opioid prescription pricing data.
Guo, Ruihan	11/12/2020	1.8	Conducted research on opioid products available in prescription pricing data.
Guo, Ruihan	11/12/2020	4.8	Reviewed opioid prescription pricing data.
Haque, Rezwan	11/12/2020	1.1	Call with expert to discuss hospital claims valuation analyses.
Haque, Rezwan	11/12/2020	1.2	Prepared agenda for call with counsel regarding hospital claims analyses.
Haque, Rezwan	11/12/2020	2.8	Reviewed analysis of hospital claims.
King, Kyla M.	11/12/2020	1.6	Reviewed public claimants' backup materials.

King, Kyla M.	11/12/2020	2.1	Checked sensitivities of NAS claimant costs.
King, Kyla M.	11/12/2020	3.8	Analyzed pharmaceutical market data.
King, Kyla M.	11/12/2020	3.9	Performed robustness checks of state claimants' estimates.
Kovacheva, Penka	11/12/2020	0.5	Reviewed analysis of NAS medical monitoring claims valuation.
Kovacheva, Penka	11/12/2020	0.6	Reviewed updates to public claims estimates.
Kovacheva, Penka	11/12/2020	1.0	Call with expert regarding personal injury claims valuation.
Kovacheva, Penka	11/12/2020	1.1	Call with expert regarding public and commercial claims analyses.
Lan, Yuehan	11/12/2020	6.0	Checked pharmaceutical market data for claims valuations.
Lee, James	11/12/2020	0.5	Reviewed analysis of third-party payer claims using cost data.
Lee, James	11/12/2020	1.0	Call with expert regarding personal injury claims data analysis.
Lee, James	11/12/2020	3.2	Prepared materials related to personal injury claims data analysis for call with expert and counsel.
McGill, Jeffrey S.	11/12/2020	2.7	Checked opioid prescription data used in third-party payer claims valuations.
McGill, Jeffrey S.	11/12/2020	3.9	Analyzed opioid prescription data used in third-party payer claims valuations.
Miller, Robert M.	11/12/2020	0.6	Checked calculations of historical public claim cost estimates.
Miller, Robert M.	11/12/2020	2.8	Checked medical cost calculations for public claims analyses.
Nandwani, Gehna	11/12/2020	3.8	Analyzed prescription data for third-party payer claims valuations.
Nandwani, Gehna	11/12/2020	4.5	Researched pricing data for third-party payer claims valuations.
Popov, Anton	11/12/2020	1.2	Calculated hospital costs.
Popov, Anton	11/12/2020	1.5	Updated methodology for estimating hospital costs.
Popov, Anton	11/12/2020	1.7	Reviewed academic literature on hospital costs.
Russell, Nolan P.	11/12/2020	3.5	Calculated inflation-adjusted personal injury claims estimates.
Russell, Nolan P.	11/12/2020	4.0	Checked personal injury claims estimates by plaintiff and injury categories.
Yanguas, Maria Lucia	11/12/2020	3.6	Reviewed and summarized sensitivities for hospital claims valuation.

Yanguas, Maria Lucia	11/12/2020	4.1	Produced hospital claims estimates using academic literature.
Yanguas, Maria Lucia	11/12/2020	4.9	Updated analyses of personal injury claims data.
Abraham, Sarah M.	11/13/2020	0.6	Discussed third-party payer claims valuation analyses with team.
Abraham, Sarah M.	11/13/2020	1.0	Call with counsel regarding personal injury and third-party payer claims valuation.
Abraham, Sarah M.	11/13/2020	4.1	Managed third-party payer claims valuation.
Aristidou, Andreas	11/13/2020	2.8	Updated summary of academic literature on pharmaceutical marketing.
Aristidou, Andreas	11/13/2020	3.3	Reviewed academic literature on pharmaceutical marketing.
Chen, Yixin	11/13/2020	1.1	Calculated summary statistics for hospital claims analysis.
Chen, Yixin	11/13/2020	3.2	Conducted sensitivity analysis of hospital cost data.
Delsman, Benjamin P.	11/13/2020	0.5	Calculated summary statistics for hospitals costs.
Delsman, Benjamin P.	11/13/2020	4.1	Performed sensitivity analyses of hospital claims estimation.
Guo, Fang	11/13/2020	0.2	Conducted academic literature research regarding hospital claims valuation.
Guo, Fang	11/13/2020	0.6	Discussed public and NAS claims valuation analyses with team.
Guo, Fang	11/13/2020	0.7	Prepared materials for call with counsel regarding public claims valuation analysis.
Guo, Fang	11/13/2020	1.0	Call with counsel regarding public claims valuation analysis.
Guo, Fang	11/13/2020	2.9	Prepared methodology for public claims sensitivity analyses.
Guo, Ruihan	11/13/2020	1.8	Analyzed opioid prescription pricing data.
Guo, Ruihan	11/13/2020	3.6	Checked opioid prescription pricing analyses.
Haque, Rezwan	11/13/2020	0.6	Discussed hospital claims valuation analyses with team.
Haque, Rezwan	11/13/2020	1.0	Call with counsel to discuss hospital claims valuation analyses.
Haque, Rezwan	11/13/2020	1.8	Reviewed hospital claims valuation analyses to prepare for call with counsel.
Haque, Rezwan	11/13/2020	3.3	Reviewed academic literature on hospital costs.

King, Kyla M.	11/13/2020	0.8	Checked sensitivities of NAS claimant costs.
King, Kyla M.	11/13/2020	3.1	Reviewed public claimants' backup materials.
King, Kyla M.	11/13/2020	3.8	Performed robustness checks of state claimants' estimates.
Kovacheva, Penka	11/13/2020	0.4	Reviewed materials for call with counsel regarding claims valuation analyses.
Kovacheva, Penka	11/13/2020	0.6	Discussed commercial claims valuation analyses with team.
Kovacheva, Penka	11/13/2020	1.1	Call with counsel regarding public and commercial claims valuation analyses.
Lan, Yuehan	11/13/2020	1.4	Summarized methodology for third-party payer claims valuations.
Lee, James	11/13/2020	0.7	Analyzed third-party payer claims valuations.
Lee, James	11/13/2020	1.0	Call with counsel regarding third-party payer and personal injury claims valuations.
Lee, James	11/13/2020	1.2	Prepared materials regarding third-party payer claims analyses for call with counsel.
Lee, James	11/13/2020	2.4	Analyzed personal injury claims data.
McGill, Jeffrey S.	11/13/2020	1.8	Updated memorandum summarizing methodology for third-party payer claims analyses.
McGill, Jeffrey S.	11/13/2020	2.1	Analyzed prescription data used in third-party payer claims valuations.
McGill, Jeffrey S.	11/13/2020	3.8	Created draft tables for third-party payer claims valuations.
Miller, Robert M.	11/13/2020	1.2	Checked calculations of historical public claim cost estimates.
Nandwani, Gehna	11/13/2020	0.9	Analyzed market level data on prescriptions for claims valuations.
Nandwani, Gehna	11/13/2020	3.9	Researched opioid product sales for claims valuations.
Nandwani, Gehna	11/13/2020	4.1	Compiled pharmaceutical market data for claims valuations.
Popov, Anton	11/13/2020	0.4	Analyzed data on hospital costs.
Popov, Anton	11/13/2020	0.6	Discussed hospital claims valuation analyses with team.
Yanguas, Maria Lucia	11/13/2020	0.6	Discussed hospital claims valuation analyses with team.
Yanguas, Maria Lucia	11/13/2020	4.0	Reviewed academic literature on sources of funding for hospital costs.

Yanguas, Maria Lucia	11/13/2020	4.2	Checked personal injury claims data analyses.
Aristidou, Andreas	11/14/2020	2.1	Reviewed academic estimates of pharmaceutical marketing.
Abraham, Sarah M.	11/15/2020	0.3	Reviewed academic literature on pharmaceutical marketing.
Aristidou, Andreas	11/15/2020	3.1	Calculated statistics for third-party payer claims valuation.
Chen, Yixin	11/15/2020	1.1	Calculated summary statistics for hospital claims valuation.
Lan, Yuehan	11/15/2020	5.1	Analyzed Purdue and Rhodes prescriptions in opioid prescriptions data.
Lee, James	11/15/2020	0.1	Reviewed summary of academic literature regarding pharmaceutical marketing.
Abraham, Sarah M.	11/16/2020	2.5	Reviewed academic literature on pharmaceutical marketing.
Abraham, Sarah M.	11/16/2020	4.7	Reviewed raw data for third-party payer claims valuation.
Aristidou, Andreas	11/16/2020	2.3	Performed sensitivity analysis on public claims.
Aristidou, Andreas	11/16/2020	2.4	Updated calculations for third-party payer claims valuation.
Aristidou, Andreas	11/16/2020	2.5	Reviewed public claimants' analysis.
Aristidou, Andreas	11/16/2020	3.0	Reviewed additional academic literature on pharmaceutical marketing.
Bazak, Eric R.	11/16/2020	0.2	Checked exhibit for third-party payer claims.
Bazak, Eric R.	11/16/2020	0.7	Researched substance use data for hospital claims valuation.
Bazak, Eric R.	11/16/2020	3.0	Calculated population shares relevant to claims valuations.
Chen, Yixin	11/16/2020	3.1	Calculated summary statistics for hospital costs.
Chen, Yixin	11/16/2020	3.5	Conducted sensitivity analyses of hospital costs.
Delsman, Benjamin P.	11/16/2020	1.9	Checked summary statistics for hospital costs and population.
Delsman, Benjamin P.	11/16/2020	3.6	Conducted sensitivity analyses of hospital costs.
Guo, Fang	11/16/2020	2.6	Analyzed pharmaceutical market data.
Guo, Fang	11/16/2020	2.8	Updated sensitivity analyses for public claims valuation.
Haque, Rezwan	11/16/2020	1.1	Reviewed data on hospital costs.
Haque, Rezwan	11/16/2020	1.9	Provided feedback on analysis of hospital claims.

Haque, Rezwan	11/16/2020	2.4	Reviewed academic literature on hospital costs.
King, Kyla M.	11/16/2020	2.3	Analyzed drug use survey data.
King, Kyla M.	11/16/2020	2.6	Analyzed pharmaceutical market data.
King, Kyla M.	11/16/2020	3.5	Updated exhibit of sensitivities of state claimants' estimates.
King, Kyla M.	11/16/2020	3.8	Performed robustness checks of state claimants' estimates.
Kovacheva, Penka	11/16/2020	1.7	Reviewed and directed analysis of pharmaceutical marketing issues.
Lan, Yuehan	11/16/2020	2.3	Analyzed prescription data for third-party payer claims valuations.
Lee, James	11/16/2020	1.1	Analyzed personal injury claims data.
Lee, James	11/16/2020	2.1	Analyzed prescriptions data for third-party payer claims valuation.
McGill, Jeffrey S.	11/16/2020	2.3	Reviewed government experts' analyses of pharmaceutical market data.
McGill, Jeffrey S.	11/16/2020	2.8	Analyzed prescription data used in third-party payer claims valuations.
Miller, Robert M.	11/16/2020	3.3	Updated public claims exhibit.
Nandwani, Gehna	11/16/2020	3.5	Estimated opioid prescription costs by payer.
Nandwani, Gehna	11/16/2020	3.8	Estimated third-party payer costs for opioid prescriptions.
Popov, Anton	11/16/2020	1.6	Estimated hospital costs.
Popov, Anton	11/16/2020	3.8	Reviewed academic literature on hospital costs.
Russell, Nolan P.	11/16/2020	0.9	Reviewed hospital claims valuation analyses.
Russell, Nolan P.	11/16/2020	2.5	Checked estimates of hospital claims for NAS patients.
Russell, Nolan P.	11/16/2020	3.8	Checked estimates of hospital claims for uninsured patients.
Yanguas, Maria Lucia	11/16/2020	1.3	Reviewed payment allocation information from personal injury claims data.
Yanguas, Maria Lucia	11/16/2020	3.5	Reviewed methodology for estimating hospital claims.
Yanguas, Maria Lucia	11/16/2020	4.3	Reviewed assumptions for estimating hospital claims.
Abraham, Sarah M.	11/17/2020	1.8	Managed valuation of third-party payer claims.
Aristidou, Andreas	11/17/2020	2.8	Reviewed academic estimates for third party payer claims valuation.
Aristidou, Andreas	11/17/2020	3.1	Reviewed analysis of valuation of third-party payer claims.

Aristidou, Andreas	11/17/2020	3.9	Performed sensitivity analysis for public claims.
Bazak, Eric R.	11/17/2020	5.0	Calculated population statistics for public claims estimates.
Bazak, Eric R.	11/17/2020	5.1	Analyzed pharmaceutical market data.
Chen, Yixin	11/17/2020	3.9	Conducted sensitivity analyses of hospital costs.
Delsman, Benjamin P.	11/17/2020	2.5	Reviewed results of hospital cost sensitivities.
Delsman, Benjamin P.	11/17/2020	4.5	Conducted sensitivity analyses for hospital costs.
Desmedt, Maaïke	11/17/2020	5.0	Estimated value of personal injury claims.
Guo, Fang	11/17/2020	0.2	Call with state claimants' consultants regarding public claims valuation analyses.
Guo, Fang	11/17/2020	2.3	Prepared work plan for analysis of pharmaceutical market data.
Guo, Fang	11/17/2020	2.8	Reviewed sensitivity analyses of public claims valuation.
Guo, Ruihan	11/17/2020	1.9	Created summaries of opioid prescription pricing data analyses.
Guo, Ruihan	11/17/2020	4.7	Analyzed opioid prescription pricing data.
Haque, Rezwan	11/17/2020	1.6	Reviewed academic literature on funding of hospitals.
Haque, Rezwan	11/17/2020	2.3	Reviewed academic literature on hospital costs.
Haque, Rezwan	11/17/2020	2.7	Reviewed estimates of hospital claims.
King, Kyla M.	11/17/2020	0.8	Reviewed public claimants' backup materials.
King, Kyla M.	11/17/2020	1.2	Analyzed pharmaceutical market data.
King, Kyla M.	11/17/2020	3.1	Updated exhibit of sensitivities of state claimants' estimates.
King, Kyla M.	11/17/2020	3.7	Performed robustness checks of state claimants' estimates.
King, Kyla M.	11/17/2020	3.9	Calculated statistics for prescription opioid shares.
Kovacheva, Penka	11/17/2020	0.2	Call with state claimants' consultants regarding public claims data.
Kovacheva, Penka	11/17/2020	2.1	Reviewed and directed analysis of third-party payers' claims valuation.
Lan, Yuehan	11/17/2020	6.3	Prepared for analysis prescription data for third-party payer claims valuations.
Lee, James	11/17/2020	1.1	Refined calculation of third-party payer claims valuation.

McGill, Jeffrey S.	11/17/2020	3.8	Analyzed opioid prescription data used in third-party payer claims valuations.
Miller, Robert M.	11/17/2020	1.3	Checked calculations of historical public claim cost estimates.
Miller, Robert M.	11/17/2020	3.7	Analyzed prescription opioid market data.
Nandwani, Gehna	11/17/2020	1.5	Estimated share of costs borne by third-party payers.
Nandwani, Gehna	11/17/2020	3.7	Reviewed survey data to assess third-party payer costs.
Popov, Anton	11/17/2020	0.5	Reviewed academic literature on estimation of hospital costs.
Popov, Anton	11/17/2020	0.6	Reviewed academic literature on funding of hospitals.
Popov, Anton	11/17/2020	3.7	Estimated hospital costs.
Yanguas, Maria Lucia	11/17/2020	4.1	Reviewed and updated hospital cost estimates.
Yanguas, Maria Lucia	11/17/2020	4.8	Reviewed updated literature on hospital costs.
Abraham, Sarah M.	11/18/2020	2.1	Reviewed pharmaceutical market data for claims valuations.
Abraham, Sarah M.	11/18/2020	4.9	Reviewed cost data for third-party payer claims valuations.
Aristidou, Andreas	11/18/2020	1.9	Reviewed pharmaceutical market data.
Aristidou, Andreas	11/18/2020	3.2	Updated methodology summary for claims of third-party payers.
Bazak, Eric R.	11/18/2020	2.0	Calculated population sensitivities for hospital claims valuation.
Bazak, Eric R.	11/18/2020	3.0	Analyzed prescription opioid market data.
Bazak, Eric R.	11/18/2020	3.1	Analyzed drug substance use data.
Chen, Yixin	11/18/2020	3.7	Created exhibits for hospital claims analyses.
Chen, Yixin	11/18/2020	4.0	Conducted sensitivity analyses of hospital costs.
Delsman, Benjamin P.	11/18/2020	1.6	Reviewed results of hospital claims analyses.
Delsman, Benjamin P.	11/18/2020	1.8	Checked exhibits displaying hospital claims analysis.
Delsman, Benjamin P.	11/18/2020	4.7	Conducted sensitivity analyses for hospital costs.
Desmedt, Maaïke	11/18/2020	1.2	Investigated pharmaceutical market data for claims valuations.
Desmedt, Maaïke	11/18/2020	2.3	Reviewed personal injury settlement agreements.
Guo, Fang	11/18/2020	2.4	Reviewed public claims sensitivity analyses.

Guo, Fang	11/18/2020	2.5	Checked public claims analyses.
Guo, Ruihan	11/18/2020	2.8	Updated analysis of opioid prescription pricing data.
Guo, Ruihan	11/18/2020	2.9	Reviewed opioid prescription pricing data analysis.
Guo, Ruihan	11/18/2020	3.9	Analyzed opioid prescription pricing data.
Haque, Rezwan	11/18/2020	1.4	Summarized estimates of hospital claims.
Haque, Rezwan	11/18/2020	1.6	Reviewed data on hospital claims.
Haque, Rezwan	11/18/2020	1.8	Reviewed academic literature on hospital costs.
Haque, Rezwan	11/18/2020	2.3	Reviewed analysis of hospital claims.
Kovacheva, Penka	11/18/2020	1.7	Reviewed updates to public claims valuation analyses.
Kovacheva, Penka	11/18/2020	1.9	Directed analyses of hospital and third-party payer claims valuation.
Lan, Yuehan	11/18/2020	1.4	Prepared for analysis prescription data for third-party payer claims valuations.
Lee, James	11/18/2020	0.5	Reviewed analyses of third-party payer claims valuations.
Lee, James	11/18/2020	2.0	Reviewed personal injury claims data summary.
McGill, Jeffrey S.	11/18/2020	3.7	Analyzed opioid prescription data used in third-party payer claims valuations.
McGill, Jeffrey S.	11/18/2020	3.8	Reviewed government experts' analyses of pharmaceutical market data.
McGill, Jeffrey S.	11/18/2020	3.9	Reviewed third-party payer claims valuations and summarized methodology.
Miller, Robert M.	11/18/2020	1.7	Updated public claims exhibit.
Miller, Robert M.	11/18/2020	1.9	Created prescription opioid market data exhibit.
Miller, Robert M.	11/18/2020	2.8	Reviewed prescription opioid market data analysis.
Miller, Robert M.	11/18/2020	3.1	Analyzed prescription opioid market data.
Nandwani, Gehna	11/18/2020	3.9	Estimated prescriptions paid by third-party payers.
Nandwani, Gehna	11/18/2020	4.4	Researched academic estimates of third-party payer shares of opioid prescriptions.
Popov, Anton	11/18/2020	1.2	Reviewed academic literature on hospital costs.
Popov, Anton	11/18/2020	2.4	Summarized estimates of hospital costs.
Popov, Anton	11/18/2020	3.4	Calculated estimates of hospital costs.

Russell, Nolan P.	11/18/2020	1.0	Reviewed hospital claims valuation analyses.
Russell, Nolan P.	11/18/2020	2.5	Checked estimates of hospital claims.
Yanguas, Maria Lucia	11/18/2020	1.5	Reviewed analysis of hospital cost estimates.
Yanguas, Maria Lucia	11/18/2020	4.6	Updated analysis of hospital claims valuation.
Yanguas, Maria Lucia	11/18/2020	4.6	Summarized personal injury claims data.
Abraham, Sarah M.	11/19/2020	1.5	Reviewed expert reports regarding pharmaceutical marketing.
Abraham, Sarah M.	11/19/2020	1.5	Call with expert regarding valuation of third-party payer claims.
Abraham, Sarah M.	11/19/2020	5.1	Managed valuation of third-party payer claims.
Aristidou, Andreas	11/19/2020	3.5	Reviewed and updated methodology for third-party payer claims estimation.
Aristidou, Andreas	11/19/2020	3.8	Updated methodology for third-party payer claims valuation.
Aristidou, Andreas	11/19/2020	3.9	Reviewed academic estimates for third-party payer claims valuation.
Bazak, Eric R.	11/19/2020	0.4	Estimated opioid use population shares.
Bazak, Eric R.	11/19/2020	2.0	Performed sensitivity analyses on state claims.
Bazak, Eric R.	11/19/2020	2.4	Calculated prescription opioid market data sensitivities for public claims analysis.
Bazak, Eric R.	11/19/2020	5.0	Calculated future population statistics for public claimant analyses.
Chen, Yixin	11/19/2020	2.4	Checked results of sensitivity analyses for hospital costs.
Chen, Yixin	11/19/2020	3.3	Created exhibits for hospital claims analysis.
Chen, Yixin	11/19/2020	3.9	Conducted sensitivity analysis of hospital costs.
Delsman, Benjamin P.	11/19/2020	1.3	Checked exhibits displaying hospital claims analysis.
Delsman, Benjamin P.	11/19/2020	4.2	Checked sensitivity analyses for hospital costs.
Delsman, Benjamin P.	11/19/2020	4.7	Conducted sensitivity analyses for hospital costs.
Guo, Fang	11/19/2020	0.7	Prepared work plan for NAS claims sensitivity analyses.
Guo, Fang	11/19/2020	1.5	Call with expert regarding public claims valuation.
Guo, Fang	11/19/2020	2.4	Reviewed analysis of public claims sensitivities.

Guo, Fang	11/19/2020	3.2	Analyzed NAS claims valuation analysis.
Guo, Ruihan	11/19/2020	2.9	Reviewed calculation of third-party payer claims valuations.
Guo, Ruihan	11/19/2020	3.9	Checked third-party payer claim valuation estimates.
Haque, Rezwan	11/19/2020	1.4	Coordinated research tasks and updates to hospital claims valuation analyses.
Haque, Rezwan	11/19/2020	1.4	Reviewed academic literature on hospital costs.
Haque, Rezwan	11/19/2020	1.5	Call with expert to discuss hospital claims valuation analyses.
Haque, Rezwan	11/19/2020	1.5	Reviewed data on healthcare spending.
Haque, Rezwan	11/19/2020	2.2	Reviewed analysis of hospital claims to prepare for call with expert.
Kovacheva, Penka	11/19/2020	1.3	Researched healthcare spending for hospital claims valuation analyses.
Kovacheva, Penka	11/19/2020	1.5	Call with expert regarding public and commercial claims analyses.
Kovacheva, Penka	11/19/2020	1.8	Directed methodology for analyses of commercial claims valuation.
Lan, Yuehan	11/19/2020	2.4	Reviewed academic estimates for use in third-party payer claims valuations.
Lee, James	11/19/2020	1.2	Prepared materials regarding personal injury claims data for call with counsel.
Lee, James	11/19/2020	3.1	Reviewed summary of personal injury claims data analysis.
Lee, James	11/19/2020	4.6	Reviewed third-party payer claims valuation analyses.
McGill, Jeffrey S.	11/19/2020	1.1	Summarized methodologies used in third-party payer claims analyses.
McGill, Jeffrey S.	11/19/2020	3.6	Reviewed data sources used in third-party payer claims analyses.
McGill, Jeffrey S.	11/19/2020	3.8	Analyzed opioid prescription data used in third-party payer claims valuations.
McGill, Jeffrey S.	11/19/2020	3.9	Updated and formatted tables of third-party payer claims valuations.
Miller, Robert M.	11/19/2020	0.3	Updated public claims exhibit.
Miller, Robert M.	11/19/2020	0.6	Checked public claims exhibit.
Miller, Robert M.	11/19/2020	1.5	Researched historical NAS incidence.
Miller, Robert M.	11/19/2020	1.6	Updated pharmaceutical market data exhibit.
Miller, Robert M.	11/19/2020	2.2	Performed sensitivity analyses on NAS claims.
Miller, Robert M.	11/19/2020	3.8	Analyzed NAS claims.
Nandwani, Gehna	11/19/2020	3.5	Prepared for analysis survey data for third-party payer claims valuation.

Nandwani, Gehna	11/19/2020	3.8	Estimated total third-party payer costs per survey data.
Popov, Anton	11/19/2020	0.5	Reviewed academic literature on estimation of hospital costs.
Popov, Anton	11/19/2020	3.0	Analyzed estimates of hospital costs.
Russell, Nolan P.	11/19/2020	1.5	Updated table summarizing estimates of hospital claims.
Russell, Nolan P.	11/19/2020	3.8	Checked estimates of hospital claims.
Yanguas, Maria Lucia	11/19/2020	0.8	Summarized academic literature on hospital costs.
Yanguas, Maria Lucia	11/19/2020	0.9	Reviewed updated sensitivities to hospital cost estimates.
Yanguas, Maria Lucia	11/19/2020	1.1	Reviewed academic literature on funding for hospitals.
Yanguas, Maria Lucia	11/19/2020	1.1	Reviewed data on NAS population and NAS costs.
Yanguas, Maria Lucia	11/19/2020	1.9	Reviewed academic literature on healthcare costs.
Yanguas, Maria Lucia	11/19/2020	2.2	Reviewed personal injury claims data.
Yanguas, Maria Lucia	11/19/2020	4.9	Updated exhibit of hospital cost estimates.
Abraham, Sarah M.	11/20/2020	1.0	Call with counsel regarding third-party payer claims valuation.
Abraham, Sarah M.	11/20/2020	4.8	Revised methodology for valuating third-party payer claims.
Aristidou, Andreas	11/20/2020	0.3	Discussed third-party payer claims valuation analyses with team.
Aristidou, Andreas	11/20/2020	3.5	Reviewed public claimants' analyses and backup documents.
Aristidou, Andreas	11/20/2020	3.8	Reviewed prior expert reports for third-party payer claims valuation.
Bazak, Eric R.	11/20/2020	3.2	Updated public claims exhibit.
Chen, Yixin	11/20/2020	1.1	Created exhibits for hospital claims analysis.
Chen, Yixin	11/20/2020	3.6	Conducted sensitivity analyses of hospital costs.
Delsman, Benjamin P.	11/20/2020	0.9	Checked hospital cost analysis.
Delsman, Benjamin P.	11/20/2020	2.2	Checked hospital claims analysis exhibit and methodology assumptions.
Guo, Fang	11/20/2020	0.3	Discussed public and NAS claims valuation analysis with team.
Guo, Fang	11/20/2020	1.0	Call with counsel regarding public claims valuation.
Guo, Fang	11/20/2020	2.1	Reviewed public claims sensitivity analyses.
Guo, Fang	11/20/2020	2.2	Reviewed NAS claims sensitivity analyses.

Guo, Ruihan	11/20/2020	0.5	Researched opioid medications marketed by Purdue.
Haque, Rezwan	11/20/2020	0.3	Discussed hospital claims valuation analyses with team.
Haque, Rezwan	11/20/2020	0.8	Reviewed list of healthcare claimants.
Haque, Rezwan	11/20/2020	1.1	Call with counsel to discuss hospital claims valuation analyses.
Haque, Rezwan	11/20/2020	1.2	Reviewed literature on funding for hospitals.
Haque, Rezwan	11/20/2020	1.3	Reviewed data on healthcare spending.
Haque, Rezwan	11/20/2020	2.8	Reviewed analysis of hospital claims.
Kovacheva, Penka	11/20/2020	0.3	Discussed public and commercial claims valuation analyses with team.
Kovacheva, Penka	11/20/2020	1.1	Call with counsel regarding public and commercial claims valuation analyses.
Kovacheva, Penka	11/20/2020	1.8	Developed preliminary methodology for analyzing municipal government and Native American tribe claims.
Kovacheva, Penka	11/20/2020	1.9	Reviewed preliminary estimates of hospital and third-party payer claims.
Lee, James	11/20/2020	1.1	Call with counsel regarding personal injury claims valuation.
Lee, James	11/20/2020	2.1	Prepared materials regarding personal injury claims data analyses for call with counsel.
Lee, James	11/20/2020	4.5	Reviewed prescription data analysis for third-party payer claims valuation.
McGill, Jeffrey S.	11/20/2020	2.1	Edited tables of third-party payer claims valuations.
McGill, Jeffrey S.	11/20/2020	3.7	Investigated new data source for third-party payer claims analysis.
McGill, Jeffrey S.	11/20/2020	3.9	Compared new and existing data sources for third-party payer claims analysis.
Miller, Robert M.	11/20/2020	0.3	Updated NAS claims exhibit.
Miller, Robert M.	11/20/2020	0.8	Checked opioid market data analysis.
Miller, Robert M.	11/20/2020	0.9	Updated NAS claims exhibit.
Miller, Robert M.	11/20/2020	2.0	Performed sensitivity analyses on NAS claims.
Nandwani, Gehna	11/20/2020	3.6	Prepared for analysis additional survey data for third-party payer claims valuation.
Nandwani, Gehna	11/20/2020	4.1	Analyzed survey data to estimate third-party payer costs.
Popov, Anton	11/20/2020	2.4	Analyzed estimates of hospital costs.

Popov, Anton	11/20/2020	2.5	Reviewed academic literature on estimation of hospital costs.
Yanguas, Maria Lucia	11/20/2020	0.3	Discussed personal injury and hospital claims valuation analyses with team.
Yanguas, Maria Lucia	11/20/2020	0.9	Checked updated analyses of personal injury claims data.
Yanguas, Maria Lucia	11/20/2020	1.1	Drafted work plan for claims valuation of hospitals and non-hospital providers.
Yanguas, Maria Lucia	11/20/2020	3.5	Updated personal injury claims data analyses.
Yanguas, Maria Lucia	11/20/2020	3.9	Reviewed and summarized literature on costs accrued by hospitals.
Abraham, Sarah M.	11/22/2020	4.1	Revised methodology for valuing third-party payer claims.
Chen, Yixin	11/22/2020	0.5	Conducted sensitivity analyses of hospital costs.
Kovacheva, Penka	11/22/2020	0.4	Researched data availability regarding prescription opioid abuse trends outside the United States.
Lee, James	11/22/2020	0.7	Reviewed analyses of prescriptions and pricing data related to third-party payer valuations.
Abraham, Sarah M.	11/23/2020	6.1	Prepared for analysis survey data containing costs of prescription drugs.
Aristidou, Andreas	11/23/2020	1.6	Checked sensitivity analysis of public claims.
Aristidou, Andreas	11/23/2020	2.3	Reviewed expert reports for third-party payer claims valuation.
Aristidou, Andreas	11/23/2020	3.7	Reviewed sensitivity analysis of public claims.
Bazak, Eric R.	11/23/2020	0.6	Analyzed treatment admissions data for hospital claims valuation.
Bazak, Eric R.	11/23/2020	1.5	Checked state claims exhibit.
Bazak, Eric R.	11/23/2020	4.5	Updated state claims exhibit.
Bazak, Eric R.	11/23/2020	5.0	Checked sensitivities for public claims analysis.
Chen, Yixin	11/23/2020	2.1	Checked analysis of hospital cost data.
Chen, Yixin	11/23/2020	2.6	Conducted research on funding for hospitals.
Delsman, Benjamin P.	11/23/2020	3.7	Updated hospital cost analysis to incorporate expert comments.
Desmedt, Maaïke	11/23/2020	2.2	Prepared for analyses personal injury claims data.
Desmedt, Maaïke	11/23/2020	5.2	Investigated survey data on costs paid for prescription opioids.
Guo, Fang	11/23/2020	0.8	Prepared work plan for claims valuation of municipalities and tribes.

Guo, Fang	11/23/2020	1.9	Reviewed NAS claims valuation analysis.
Guo, Fang	11/23/2020	2.9	Reviewed public claims valuation analysis.
Guo, Ruihan	11/23/2020	2.9	Conducted research on historical opioid product sales.
Haque, Rezwan	11/23/2020	0.7	Reviewed work plan for hospital claims valuation analyses.
Haque, Rezwan	11/23/2020	0.8	Reviewed sample of healthcare claimants.
Haque, Rezwan	11/23/2020	2.4	Reviewed updates to hospital claims valuation analyses.
King, Kyla M.	11/23/2020	2.3	Reviewed state claimants' backup materials.
King, Kyla M.	11/23/2020	3.4	Updated exhibit of sensitivities of state claimants' estimates.
King, Kyla M.	11/23/2020	3.7	Checked sensitivity analyses of state claimants' estimates.
King, Kyla M.	11/23/2020	3.8	Performed robustness checks of state claimants' estimates.
Kovacheva, Penka	11/23/2020	1.6	Reviewed methodology for commercial claims valuation.
Kovacheva, Penka	11/23/2020	1.7	Reviewed government expert's claim estimates for municipalities and Native American tribes.
Lan, Yuehan	11/23/2020	3.1	Analyzed third-party payer costs in survey data.
Lee, James	11/23/2020	2.4	Prepared work plan for analysis of third-party payer claims valuation.
Lee, James	11/23/2020	4.8	Analyzed drug pricing and prescriptions data for third-party payer valuation analyses.
McGill, Jeffrey S.	11/23/2020	2.1	Reviewed statistical code used in third-party payer claims valuations.
McGill, Jeffrey S.	11/23/2020	3.7	Updated tables of third-party payer claims valuations.
McGill, Jeffrey S.	11/23/2020	3.8	Analyzed pharmaceutical market data for claims valuations.
McGill, Jeffrey S.	11/23/2020	3.9	Analyzed prescription data for third-party payer claims valuations.
Miller, Robert M.	11/23/2020	0.4	Checked NAS claims exhibit.
Miller, Robert M.	11/23/2020	1.3	Checked state claims exhibit.
Miller, Robert M.	11/23/2020	1.3	Checked public claims exhibit.
Miller, Robert M.	11/23/2020	3.3	Updated NAS claims exhibit.
Nandwani, Gehna	11/23/2020	2.2	Analyzed survey data to estimate third-party payer costs.

Nandwani, Gehna	11/23/2020	4.0	Researched methodology behind collection of survey data used in third-party payer claims valuations.
Popov, Anton	11/23/2020	1.9	Reviewed academic literature on components of hospital costs.
Russell, Nolan P.	11/23/2020	0.8	Reviewed hospital claims valuation.
Russell, Nolan P.	11/23/2020	1.3	Researched historical data for hospital costs.
Russell, Nolan P.	11/23/2020	2.5	Checked future opioid use projections.
Yanguas, Maria Lucia	11/23/2020	1.3	Reviewed data and literature regarding healthcare providers' costs.
Yanguas, Maria Lucia	11/23/2020	1.9	Reviewed literature on NAS cost estimates.
Yanguas, Maria Lucia	11/23/2020	4.5	Reviewed hospital claims valuation estimates and sensitivities.
Abraham, Sarah M.	11/24/2020	2.1	Updated personal injury claims valuation based on new data.
Abraham, Sarah M.	11/24/2020	3.1	Reviewed academic literature on pharmaceutical marketing.
Abraham, Sarah M.	11/24/2020	3.2	Analyzed data on costs borne by third-party payers.
Abraham, Sarah M.	11/24/2020	5.2	Prepared preliminary estimates of third-party payer claims valuation.
Aristidou, Andreas	11/24/2020	1.0	Reviewed expert reports for third-party payer claims valuation estimation.
Aristidou, Andreas	11/24/2020	1.1	Reviewed analysis of hospital costs.
Aristidou, Andreas	11/24/2020	2.2	Reviewed sensitivity analysis of public claims.
Aristidou, Andreas	11/24/2020	3.9	Reviewed academic literature on NAS costs.
Bazak, Eric R.	11/24/2020	0.6	Calculated population statistics using treatment admissions data.
Bazak, Eric R.	11/24/2020	2.2	Updated NAS claims exhibit.
Bazak, Eric R.	11/24/2020	5.5	Updated state claims exhibit.
Bazak, Eric R.	11/24/2020	5.0	Checked state claims exhibit.
Chen, Yixin	11/24/2020	1.5	Conducted research on funding for hospitals.
Chen, Yixin	11/24/2020	4.0	Checked exhibits for hospital claims estimation.
Delsman, Benjamin P.	11/24/2020	1.9	Reviewed claim documentation from certain healthcare providers.
Delsman, Benjamin P.	11/24/2020	2.6	Reviewed academic literature on healthcare provider costs.
Desmedt, Maaïke	11/24/2020	5.2	Prepared for analyses survey data on costs paid for prescription opioids.
Desmedt, Maaïke	11/24/2020	5.6	Summarized data on opioid prescriptions and cost coverage.

Guo, Fang	11/24/2020	0.2	Call with states' consultants regarding public claims valuation.
Guo, Fang	11/24/2020	1.8	Reviewed public claims valuation estimates.
Guo, Fang	11/24/2020	1.8	Analyzed NAS claims estimates.
Guo, Ruihan	11/24/2020	1.3	Checked analysis of historical opioid product sales.
Guo, Ruihan	11/24/2020	1.8	Conducted research on historical opioid product sales.
Haque, Rezwan	11/24/2020	0.8	Reviewed list of healthcare providers.
Haque, Rezwan	11/24/2020	1.2	Reviewed academic literature on NAS costs.
Haque, Rezwan	11/24/2020	1.7	Reviewed literature on hospital costs.
Haque, Rezwan	11/24/2020	2.2	Reviewed analysis of hospital claims.
King, Kyla M.	11/24/2020	2.9	Checked sensitivity analyses of NAS claimants' estimates.
King, Kyla M.	11/24/2020	3.5	Performed robustness checks of state claimants' estimates.
King, Kyla M.	11/24/2020	3.7	Updated exhibit of sensitivities of state claimants' estimates.
King, Kyla M.	11/24/2020	3.9	Checked sensitivity analyses of state claimants' estimates.
Kovacheva, Penka	11/24/2020	0.2	Call with states' consultants regarding public claims valuation.
Kovacheva, Penka	11/24/2020	1.2	Prepared materials for call with counsel regarding claims valuation analyses.
Kovacheva, Penka	11/24/2020	1.7	Reviewed methodology for hospital and third-party payer claims valuation.
Lan, Yuehan	11/24/2020	1.6	Checked calculations of third-party payer cost per prescription.
Lee, James	11/24/2020	2.1	Prepared materials regarding third-party payer claims estimations for call with counsel.
Lee, James	11/24/2020	4.3	Reviewed and outlined next steps for third-party payer claims valuation analyses.
McGill, Jeffrey S.	11/24/2020	3.8	Updated sensitivity analyses of third-party payer claims valuation.
McGill, Jeffrey S.	11/24/2020	3.9	Conducted sensitivity analyses of third-party payer claims valuation.
McGill, Jeffrey S.	11/24/2020	3.9	Revised statistical code used in third-party payer claims valuations.
Miller, Robert M.	11/24/2020	1.2	Updated NAS claims exhibit.
Miller, Robert M.	11/24/2020	2.2	Updated state claims exhibits.
Miller, Robert M.	11/24/2020	3.8	Checked state claims exhibits.

Nandwani, Gehna	11/24/2020	1.9	Linked third-party payer cost data to prescriptions data.
Nandwani, Gehna	11/24/2020	3.4	Analyzed survey data to estimate third-party payer costs.
Nandwani, Gehna	11/24/2020	4.6	Estimated third-party payer costs.
Popov, Anton	11/24/2020	0.9	Reviewed academic literature on funding for hospitals.
Popov, Anton	11/24/2020	1.6	Reviewed academic literature on components of hospital costs.
Popov, Anton	11/24/2020	2.3	Reviewed academic literature on healthcare providers.
Yanguas, Maria Lucia	11/24/2020	0.3	Reviewed and updated personal injury claims valuation analyses.
Yanguas, Maria Lucia	11/24/2020	1.8	Reviewed academic literature on funding for hospitals.
Yanguas, Maria Lucia	11/24/2020	2.2	Researched medical costs borne by hospitals.
Yanguas, Maria Lucia	11/24/2020	3.2	Applied sensitivities to hospital cost estimates.
Yanguas, Maria Lucia	11/24/2020	3.2	Updated exhibits for hospital claims valuation.
Abraham, Sarah M.	11/25/2020	1.2	Call with counsel regarding third-party payer claims valuation.
Abraham, Sarah M.	11/25/2020	1.9	Prepared materials for call with counsel on commercial claims valuations.
Abraham, Sarah M.	11/25/2020	2.1	Prepared materials for call with expert on third-party payer claims.
Abraham, Sarah M.	11/25/2020	4.0	Managed valuation of third party payer claims.
Aristidou, Andreas	11/25/2020	0.5	Discussed third-party payer claims valuation analyses with team.
Aristidou, Andreas	11/25/2020	3.4	Analyzed NAS costs for hospital claims.
Aristidou, Andreas	11/25/2020	3.6	Reviewed literature on NAS costs.
Bazak, Eric R.	11/25/2020	2.1	Updated state claims exhibit.
Bazak, Eric R.	11/25/2020	5.0	Checked state claims exhibit.
Bazak, Eric R.	11/25/2020	5.0	Checked historical state healthcare cost calculations.
Desmedt, Maaïke	11/25/2020	4.2	Prepared for analyses survey data on opioid prescription costs.
Desmedt, Maaïke	11/25/2020	4.3	Summarized survey data on costs for prescription opioids.
Guo, Fang	11/25/2020	0.5	Discussed public and NAS claims valuation analysis with team.
Guo, Fang	11/25/2020	1.0	Reviewed public claims valuation analysis.
Guo, Fang	11/25/2020	1.3	Call with counsel regarding public claims valuation analysis.

Guo, Fang	11/25/2020	3.5	Reviewed and edited exhibits of public claims and NAS claims valuation.
Guo, Ruihan	11/25/2020	0.6	Analyzed third-party payer claims valuation estimates.
Haque, Rezwan	11/25/2020	0.5	Discussed healthcare provider valuation analyses with team.
Haque, Rezwan	11/25/2020	1.1	Call with counsel to discuss hospital claims valuation analyses.
Haque, Rezwan	11/25/2020	1.1	Reviewed literature on NAS costs.
Haque, Rezwan	11/25/2020	2.2	Reviewed analysis of hospital claims.
Haque, Rezwan	11/25/2020	2.3	Reviewed literature on hospital costs.
King, Kyla M.	11/25/2020	2.6	Reviewed NAS claims estimates.
King, Kyla M.	11/25/2020	3.8	Updated exhibit of sensitivities of state claimants' estimates.
King, Kyla M.	11/25/2020	3.9	Finalized NAS claims sensitivities exhibit.
King, Kyla M.	11/25/2020	4.0	Checked sensitivity analyses of NAS claims estimates.
Kovacheva, Penka	11/25/2020	1.1	Prepared materials for call with counsel regarding claims valuation analyses.
Kovacheva, Penka	11/25/2020	1.3	Call with counsel regarding private and public claims valuation analyses.
Kovacheva, Penka	11/25/2020	1.9	Reviewed preliminary estimates of hospital and third-party payer claims.
Lan, Yuehan	11/25/2020	2.2	Checked analysis of prescription data in third-party payer claims valuations.
Lee, James	11/25/2020	0.5	Discussed third-party payer claims valuation with team.
Lee, James	11/25/2020	1.1	Reviewed prescription data related to third-party payer claims valuation analyses.
Lee, James	11/25/2020	1.2	Call with counsel regarding third-party payer claims valuations.
Lee, James	11/25/2020	6.7	Analyzed prescription data related to third-party payer claims valuations.
McGill, Jeffrey S.	11/25/2020	1.9	Updated statistical code used for third-party payer claims valuations.
McGill, Jeffrey S.	11/25/2020	3.7	Designed new sensitivity analyses for third-party payer claims valuations.
McGill, Jeffrey S.	11/25/2020	3.9	Updated sensitivity analyses of third-party payer claims valuation.
Miller, Robert M.	11/25/2020	0.6	Updated NAS claims exhibit.
Miller, Robert M.	11/25/2020	1.8	Updated state claims exhibits.
Miller, Robert M.	11/25/2020	4.0	Checked state claims exhibits.
Nandwani, Gehna	11/25/2020	1.8	Estimated cost shares for third-party payers.

Nandwani, Gehna	11/25/2020	4.1	Linked third-party payer cost data to prescriptions data.
Popov, Anton	11/25/2020	0.5	Discussed hospital claims valuation analyses with team.
Popov, Anton	11/25/2020	1.9	Reviewed academic literature on healthcare providers.
Popov, Anton	11/25/2020	3.1	Reviewed academic literature on components of hospital costs.
Yanguas, Maria Lucia	11/25/2020	0.5	Discussed hospital claims valuation analyses with team.
Yanguas, Maria Lucia	11/25/2020	3.4	Updated hospital cost analysis.
Yanguas, Maria Lucia	11/25/2020	4.7	Updated sensitivities for hospital claims valuation analysis.
Yanguas, Maria Lucia	11/25/2020	4.8	Reviewed academic literature on NAS cost estimates.
Lee, James	11/26/2020	0.8	Analyzed prescription data for third-party payer valuation analysis.
Abraham, Sarah M.	11/27/2020	1.5	Call with expert regarding third-party payer claims valuation.
Abraham, Sarah M.	11/27/2020	4.3	Reviewed data on payments made for prescriptions.
Bazak, Eric R.	11/27/2020	4.8	Checked historical state healthcare costs.
Guo, Fang	11/27/2020	1.5	Call with expert regarding public claims valuation analysis.
Haque, Rezwan	11/27/2020	0.8	Reviewed academic literature related to hospital costs.
Haque, Rezwan	11/27/2020	1.1	Reviewed analysis of hospital claims.
Haque, Rezwan	11/27/2020	1.5	Call with expert to discuss hospital claims valuation analyses.
King, Kyla M.	11/27/2020	1.9	Updated exhibit summarizing sensitivities of state claimants' estimates.
King, Kyla M.	11/27/2020	3.2	Finalized NAS claims sensitivities exhibit.
King, Kyla M.	11/27/2020	3.6	Finalized state claims sensitivities exhibit.
King, Kyla M.	11/27/2020	3.9	Performed robustness checks of state claimants' estimates.
Kovacheva, Penka	11/27/2020	0.3	Reviewed expert's methodology for estimating municipal governments' claims.
Kovacheva, Penka	11/27/2020	1.5	Call with expert regarding public and commercial claims analyses.
Lee, James	11/27/2020	0.4	Analyzed prescriptions data for third-party payer claims valuation.

Lee, James	11/27/2020	1.5	Call with expert to discuss third-party payer claims valuations.
McGill, Jeffrey S.	11/27/2020	2.8	Analyzed opioid prescription data used for third-party payer claims valuations.
McGill, Jeffrey S.	11/27/2020	3.4	Investigated data sources used for third-party payer claims valuations.
Lee, James	11/28/2020	1.6	Reviewed analysis of costs related to third-party payer claims valuation.
Guo, Ruihan	11/29/2020	4.5	Checked third-party payer claims valuation estimates.
King, Kyla M.	11/29/2020	1.5	Finalized NAS claims sensitivities exhibit.
King, Kyla M.	11/29/2020	1.6	Finalized state claims sensitivities exhibit.
Abraham, Sarah M.	11/30/2020	1.2	Updated analysis of personal injury claims valuation.
Abraham, Sarah M.	11/30/2020	2.2	Managed valuation of third party payer claims.
Abraham, Sarah M.	11/30/2020	4.2	Created and edited exhibits on third-party payer claim valuations.
Abraham, Sarah M.	11/30/2020	4.3	Managed analyses of costs for third-party payer valuations.
Aristidou, Andreas	11/30/2020	2.0	Reviewed literature on NAS costs.
Aristidou, Andreas	11/30/2020	2.1	Reviewed sensitivity analyses of public claims.
Aristidou, Andreas	11/30/2020	3.3	Reviewed prior expert reports for third-party payer claims valuation estimation.
Bazak, Eric R.	11/30/2020	0.8	Updated state claims exhibit.
Bazak, Eric R.	11/30/2020	2.4	Edited public claims exhibits.
Bazak, Eric R.	11/30/2020	2.5	Checked public claims analyses.
Delsman, Benjamin P.	11/30/2020	1.2	Researched overlap between healthcare providers.
Desmedt, Maaïke	11/30/2020	7.2	Investigated survey data on payments for prescriptions.
Desmedt, Maaïke	11/30/2020	7.2	Investigated academic estimates for third-party payer valuation.
Guo, Fang	11/30/2020	0.3	Reviewed hospital claims valuation estimates.
Guo, Fang	11/30/2020	3.9	Reviewed and edited exhibits of public claims and NAS claims.
Guo, Ruihan	11/30/2020	2.8	Analyzed third-party payer claims valuation estimates.
Guo, Ruihan	11/30/2020	4.9	Checked third-party payer claims valuation estimates and sensitivities.
Haque, Rezwan	11/30/2020	1.6	Reviewed hospital claims valuation exhibits.

Haque, Rezwan	11/30/2020	1.8	Reviewed claims from healthcare providers.
Haque, Rezwan	11/30/2020	2.7	Reviewed analysis of hospital claims.
King, Kyla M.	11/30/2020	3.1	Checked hospital claims sensitivities exhibit.
King, Kyla M.	11/30/2020	3.6	Checked NAS claims sensitivities exhibit.
King, Kyla M.	11/30/2020	3.7	Checked state claims sensitivities exhibit.
Kovacheva, Penka	11/30/2020	0.5	Reviewed Canadian government claimants' proofs of claim.
Kovacheva, Penka	11/30/2020	0.6	Reviewed and provided comments on exhibit summarizing personal injury claims estimates.
Kovacheva, Penka	11/30/2020	1.6	Reviewed and provided comments on exhibits summarizing public claims estimates.
Kovacheva, Penka	11/30/2020	3.5	Reviewed and provided comments on exhibits summarizing commercial claim estimates.
Lan, Yuehan	11/30/2020	3.0	Edited exhibits of third-party payer claims analyses.
Lee, James	11/30/2020	1.9	Reviewed personal injury claims data analysis.
Lee, James	11/30/2020	4.7	Reviewed analyses of costs for third-party payer claims valuations.
McGill, Jeffrey S.	11/30/2020	2.1	Updated third-party payer exhibits.
McGill, Jeffrey S.	11/30/2020	2.9	Reviewed underlying templates used in third-party payer exhibits.
McGill, Jeffrey S.	11/30/2020	3.8	Adjusted template used in third-party payer analyses.
McGill, Jeffrey S.	11/30/2020	3.9	Analyzed data underlying third-party payer analyses.
Miller, Robert M.	11/30/2020	0.6	Checked NAS claims exhibit.
Miller, Robert M.	11/30/2020	0.9	Updated NAS claims exhibit.
Miller, Robert M.	11/30/2020	3.2	Updated state claims exhibits.
Nandwani, Gehna	11/30/2020	1.7	Compared sources of cost data for third-party payer claims valuations.
Nandwani, Gehna	11/30/2020	3.9	Performed robustness analyses of third-party payer claims valuations.
Nandwani, Gehna	11/30/2020	4.2	Analyzed survey data to estimate third-party payer costs.
Popov, Anton	11/30/2020	0.7	Reviewed estimates of hospital costs.
Popov, Anton	11/30/2020	1.2	Reviewed academic literature on costs of healthcare provider services.
Russell, Nolan P.	11/30/2020	0.6	Reviewed hospital claims valuation.

Russell, Nolan P.	11/30/2020	2.3	Checked sensitivities of hospital claims estimates.
Yanguas, Maria Lucia	11/30/2020	0.7	Updated personal injury claims valuation analysis.
Yanguas, Maria Lucia	11/30/2020	5.8	Updated hospital claims valuation analysis.

Total **1923.8**

Grand Total **1938.2**